Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients

Breast Cancer Research

Volumn 11, Issue 6, 2009, Pages

  Schmidt, Marjanka K ^a   Tommiska, Johanna ^b   Broeks, Annegien ^a   van Leeuwen, Flora E ^a   Van't Veer, Laura J ^a   Pharoah, Paul D P ^c   Easton, Douglas F ^c   Shah, Mitul ^c   Humphreys, Manjeet ^c   Dörk, Thilo ^d   Reincke, Scarlett A ^d   Fagerholm, Rainer ^b   Blomqvist, Carl ^b   Nevanlinna, Heli ^b  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN MDM2; PROTEIN P53; MDM2 PROTEIN, HUMAN; TP53 PROTEIN, HUMAN;

ADULT; AGED; ALLELE; ARTICLE; BREAST CANCER; CANCER CELL; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; DNA REPAIR; FEMALE; FOLLOW UP; GENE FUNCTION; GENETIC VARIABILITY; GENOTYPE; GERM LINE; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PREDICTION; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; BIOSYNTHESIS; BREAST TUMOR; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; MUTATION; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; TUMOR SUPPRESSOR GENE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; GENES, P53; GENOTYPE; GERM-LINE MUTATION; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MDM2; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 77954578718     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2460     Document Type: Article

References (45)

1. Schmidt MK, Reincke S, Broeks A, Braaf LM, Hogervorst FBL, Tollenaar RAEM, Johnson N, Fletcher O, Peto J, Tommiska J, Blomqvist C, Nevanlinna HA, Healey CS, Dunning AM, Pharoah PD, Easton DF, Dork T, Van't Veer LJ, . on behalf of the Breast Cancer Association Consortium Do MDM2 SNP309 and TP53 R72P Interact in Breast Cancer Susceptibility? A Large Pooled Series from the Breast Cancer Association Consortium. Cancer Res 2007, 67:9584-9590. 10.1158/0008-5472.CAN-07-0738, 17909070, on behalf of the Breast Cancer Association Consortium.
2. Fagerholm R, Hofstetter B, Tommiska J, Aaltonen K, Vrtel R, Syrjakoski K, Kallioniemi A, Kilpivaara O, Mannermaa A, Kosma VM, Uusitupa M, Eskelinen M, Kataja V, Aittomaki K, von Smitten K, Heikkila P, Lukas J, Holli K, Bartkova J, Blomqvist C, Bartek J, Nevanlinna H. NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer. Nat Genet 2008, 40:844-853. 10.1038/ng.155, 18511948.
3. Bond GL, Hu W, Levine AJ. MDM2 is a central node in the p53 pathway: 12 years and counting. Curr Cancer Drug Targets 2005, 5:3-8. 10.2174/1568009053332627, 15720184.
4. Walker KK, Levine AJ. Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proc Natl Acad Sci USA 1996, 93:15335-15340. 10.1073/pnas.93.26.15335, 26405, 8986812.
5. Sakamuro D, Sabbatini P, White E, Prendergast GC. The polyproline region of p53 is required to activate apoptosis but not growth arrest. Oncogene 1997, 15:887-898. 10.1038/sj.onc.1201263, 9285684.
6. Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 1999, 19:1092-1100. 116039, 9891044.
7. Pim D, Banks L. p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer 2004, 108:196-199. 10.1002/ijc.11548, 14639602.
8. Bergamaschi D, Samuels Y, Sullivan A, Zvelebil M, Breyssens H, Bisso A, Del Sal G, Syed N, Smith P, Gasco M, Crook T, Lu X. iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53. Nat Genet 2006, 38:1133-1141. 10.1038/ng1879, 16964264.
9. Siddique MM, Balram C, Fiszer-Maliszewska L, Aggarwal A, Tan A, Tan P, Soo KC, Sabapathy K. Evidence for selective expression of the p53 codon 72 polymorphs: implications in cancer development. Cancer Epidemiol Biomarkers Prev 2005, 14:2245-2252. 10.1158/1055-9965.EPI-05-0153, 16172238.
10. Tommiska J, Eerola H, Heinonen M, Salonen L, Kaare M, Tallila J, Ristimaki A, von Smitten K, Aittomaki K, Heikkila P, Blomqvist C, Nevanlinna H. Breast Cancer Patients with p53 Pro72 Homozygous Genotype Have a Poorer Survival. Clin Cancer Res 2005, 11:5098-5103. 10.1158/1078-0432.CCR-05-0173, 16033823.
11. The Breast Cancer Association Consortium Commonly Studied Single-Nucleotide Polymorphisms and Breast Cancer: Results From the Breast Cancer Association Consortium. J Natl Cancer Inst 2006, 98:1382-1396. The Breast Cancer Association Consortium.
12. Goode E, Dunning A, Kuschel B, Healey C, Day N, Ponder B, Easton D, Pharoah P. Effect of Germ-Line Genetic Variation on Breast Cancer Survival in a Population-based Study. Cancer Res 2002, 62:3052-3057.
13. Toyama T, Zhang Z, Nishio M, Hamaguchi M, Kondo N, Iwase H, Iwata H, Takahashi S, Yamashita H, Fujii Y. Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients. Breast Cancer Res 2007, 9:R34. 10.1186/bcr1682, 1929098, 17537232.
14. Xu Y, Yao L, Ouyang T, Li J, Wang T, Fan Z, Lin B, Lu Y, Xie Y. p53 Codon 72 Polymorphism Predicts the Pathologic Response to Neoadjuvant Chemotherapy in Patients with Breast Cancer. Clin Cancer Res 2005, 11:7328-7333. 10.1158/1078-0432.CCR-05-0507, 16243804.
15. Kyndi M, Alsner J, Hansen LL, Sorensen FB, Overgaard J. LOH rather than genotypes of TP53 codon 72 is associated with disease-free survival in primary breast cancer. Acta Oncol 2006, 45:602-609. 10.1080/02841860600660811, 16864176.
16. Xu Y, Yao L, Zhao A, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Lu Y, Xie Y. Effect of p53 codon 72 genotype on breast cancer survival depends on p53 gene status. Int J Cancer 2008, 122:2761-2766. 10.1002/ijc.23454, 18348141.
17. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, Onel K, Yip L, Hwang SJ, Strong LC, Lozano G, Levine AJ. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004, 119:591-602. 10.1016/j.cell.2004.11.022, 15550242.
18. Bougeard G, Baert-Desurmont S, Tournier I, Vasseur S, Martin C, Brugieres L, Chompret A, Bressac-de Paillerets B, Stoppa-Lyonnet D, Bonaiti-Pellie C, Frebourg T. Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome. J Med Genet 2006, 43:531-533. 10.1136/jmg.2005.037952, 1904480,1904480, 16258005.
19. Ruijs MWG, Schmidt MK, Nevanlinna H, Tommiska J, Aittomäki K, Pruntel R, Verhoef S, Van't Veer LJ. The single nucleotide polymorphism 309 in the MDM2 gene contributes to the Li-Fraumeni syndrome and related phenotypes. Eur J Hum Genet 2007, 15:110-114. 10.1038/sj.ejhg.5201715, 17003841.
20. Wasielewski M, Nagel JH, Brekelmans C, Klijn JG, Ouweland A, Meijers-Heijboer H, Schutte M. MDM2 SNP309 accelerates familial breast carcinogenesis independently of estrogen signaling. Breast Cancer Res Treat 2006, 104:153-175. 10.1007/s10549-006-9407-5, 17080308.
21. Cox DG, Deer D, Guo Q, Tworoger SS, Hankinson SE, Hunter DJ, De Vivo I. The p53 Arg72Pro and MDM2 -309 polymorphisms and risk of breast cancer in the nurses' health studies. Cancer Causes Control 2007, 18:621-625. 10.1007/s10552-007-9004-x, 17387621.
22. Boersma B, Howe T, Goodman J, Yfantis H, Lee D, Chanock S, Ambs S. Association of Breast Cancer Outcome With Status of p53 and MDM2 SNP309. J Natl Cancer Inst 2006, 98:911-919.
23. Gryshchenko I, Hofbauer S, Stoecher M, Daniel P, Steurer M, Gaiger A, Eigenberger K, Greil R, Tinhofer I. MDM2 SNP309 Is Associated With Poor Outcome in B-Cell Chronic Lymphocytic Leukemia. J Clin Oncol 2008, 26:2252-2257. 10.1200/JCO.2007.11.5212, 18467716.
24. Nechushtan H, Hamburger T, Mendelson S, Kadouri L, Sharon N, Pikarsky E, Peretz T. Effects of the single nucleotide polymorphism at MDM2 309 on breast cancer patients with/without BRCA1/2 mutations. BMC Cancer 2009, 9:60. 10.1186/1471-2407-9-60, 2667534, 19226467.
25. Garcia-Closas M, Hall P, Nevanlinna H, Pooley K, Morrison J, Richesson DA, Bojesen SE, Nordestgaard BG, Axelsson CK, Arias JI, Milne RL, Ribas G, Gonzalez-Neira A, Benitez J, Zamora P, Brauch H, Justenhoven C, Hamann U, Ko YD, Bruening T, Haas S, Dork T, Schurmann P, Hillemanns P, Bogdanova N, Bremer M, Karstens JH, Fagerholm R, Aaltonen K, Aittomaki K. Heterogeneity of breast cancer associations with five susceptibility Loci by clinical and pathological characteristics. PLoS Genet 2008, 4:e1000054. 10.1371/journal.pgen.1000054, 2291027, 18437204.
26. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 2005, 23:9067-9072. 10.1200/JCO.2004.01.0454, 16172462.
27. Dumont P, Leu JI, Della Pietra AC, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003, 33:357-365. 10.1038/ng1093, 12567188.
28. Sullivan A, Syed N, Gasco M, Bergamaschi D, Trigiante G, Attard M, Hiller L, Farrell PJ, Smith P, Lu X, Crook T. Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene 2004, 23:3328-3337. 10.1038/sj.onc.1207428, 15077186.
29. Bergamaschi D, Gasco M, Hiller L, Sullivan A, Syed N, Trigiante G, Yulug I, Merlano M, Numico G, Comino A, Attard M, Reelfs O, Gusterson B, Bell AK, Heath V, Tavassoli M, Farrell PJ, Smith P, Lu X, Crook T. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 2003, 3:387-402. 10.1016/S1535-6108(03)00079-5, 12726864.
30. Schneider-Stock R, Mawrin C, Motsch C, Boltze C, Peters B, Hartig R, Buhtz P, Giers A, Rohrbeck A, Freigang B, Roessner A. Retention of the arginine allele in codon 72 of the p53 gene correlates with poor apoptosis in head and neck cancer. Am J Pathol 2004, 164:1233-1241. 1615339, 15039212.
31. Bonafe M, Ceccarelli C, Farabegoli F, Santini D, Taffurelli M, Barbi C, Marzi E, Trapassi C, Storci G, Olivieri F, Franceschi C. Retention of the p53 Codon 72 Arginine Allele Is Associated with a Reduction of Disease-Free and Overall Survival in Arginine/Proline Heterozygous Breast Cancer Patients. Clin Cancer Res 2003, 9:4860-4864.
32. Olivier M, Langerod A, Carrieri P, Bergh J, Klaar S, Eyfjord J, Theillet C, Rodriguez C, Lidereau R, Bieche I, Varley J, Bignon Y, Uhrhammer N, Winqvist R, Jukkola-Vuorinen A, Niederacher D, Kato S, Ishioka C, Hainaut P, Borresen-Dale A. The Clinical Value of Somatic TP53 Gene Mutations in 1,794 Patients with Breast Cancer. Clin Cancer Res 2006, 12:1157-1167. 10.1158/1078-0432.CCR-05-1029, 16489069.
33. Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P, Olivier M. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 2007, 26:2157-2165. 10.1038/sj.onc.1210302, 17401424.
34. Soussi T, Beroud C. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer 2001, 1:233-240. 10.1038/35106009, 11902578.
35. Sjogren S, Inganas M, Norberg T, Lindgren A, Nordgren H, Holmberg L, Bergh J. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst 1996, 88:173-182. 10.1093/jnci/88.3-4.173, 8632491.
36. Bidard FC, Matthieu MC, Chollet P, Raoefils I, Abrial C, Domont J, Spielmann M, Delaloge S, Andre F, Penault-Llorca F. p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes. Ann Oncol 2008, 19:1261-1265. 10.1093/annonc/mdn039, 18325917.
37. Bertheau P, Espie M, Turpin E, Lehmann J, Plassa LF, Varna M, Janin A, de The H. TP53 status and response to chemotherapy in breast cancer. Pathobiology 2008, 75:132-139. 10.1159/000123851, 18544968.
38. Kbiosciences, Cambridge, UK. , http://www.kbioscience.co.uk
39. Taqman, Applied Biosystems. , http://www2.appliedbiosystems.com
40. Illumina. , http://www.illumina.com
41. Schmidt MK, Tollenaar RAEM, de Kemp SR, Broeks A, Cornelisse CJ, Smit VTHBM, Peterse JL, van Leeuwen FE, Van't Veer LJ. Breast Cancer Survival and Tumor Characteristics in Premenopausal Women Carrying the CHEK2*1100delC Germline Mutation. J Clin Oncol 2007, 25:64-69. 10.1200/JCO.2006.06.3024, 17132695.
42. Steinmann D, Bremer M, Rades D, Skawran B, Siebrands C, Karstens JH, Dork T. Mutations of the BRCA1 and BRCA2 genes in patients with bilateral breast cancer. Br J Cancer 2001, 85:850-858. 10.1054/bjoc.2001.2016, 2375067, 11556836.
43. Dork T, Bendix R, Bremer M, Rades D, Klopper K, Nicke M, Skawran B, Hector A, Yamini P, Steinmann D, Weise S, Stuhrmann M, Karstens JH. Spectrum of ATM gene mutations in a hospital-based series of unselected breast cancer patients. Cancer Res 2001, 61:7608-7615.
44. Syrjakoski K, Vahteristo P, Eerola H, Tamminen A, Kivinummi K, Sarantaus L, Holli K, Blomqvist C, Kallioniemi OP, Kainu T, Nevanlinna H. Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients. J Natl Cancer Inst 2000, 92:1529-1531. 10.1093/jnci/92.18.1529, 10995809.
45. Cebrian A, Pharoah P, Ahmed S, Ropero S, Fraga M, Smith P, Conroy D, Luben R, Perkins B, Easton D, Dunning A, Esteller M, Ponder B. Genetic variants in epigenetic genes and breast cancer risk. Carcinogenesis 2006, 27:1661-1669. 10.1093/carcin/bgi375, 16501248.